Publication:
Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren’s syndrome: a pilot study

Loading...
Thumbnail Image
Date
2018-07-20
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Tvarijonaviciute, Asta ; Zamora, Carmen ; Martinez-Subiela, Silvia ; Tecles, Fernando ; Pina, Francisca ; Lopez Jornet, Pia
item.page.secondaryauthor
item.page.director
Publisher
https://link.springer.com/
publication.page.editor
DOI
https://doi.org/10.1007/s00784-018-2570-3
item.page.type
info:eu-repo/semantics/article
Description
© 2018. The authors. This document is the Published version of a published Work that appeared in final form in Clinical Oral Investigations. To access the final edited and published work see https://doi.org/10.1007/s00784-018-2570-3
Abstract
Objectives To evaluate salivary adiponectin and adenosine deaminase (ADA) in women suffering from Sjögren’s syndrome (SS). Methods Salivary adiponectin and ADA were measured in patients with SS (n = 17) and compared to their values in healthy controls (n = 13) and patients suffering from drug-induced xerostomia (non-SS sicca group; n = 19). A clinical history was made for each patient, patients were examined clinically, and xerostomia inventory (XI) was performed. Results Salivary adiponectin corrected by total protein was higher in patients with SS than in healthy individuals (P < 0.05) or patients with non-SS sicca (P < 0.01) and correlated with XI (r = 0.555; P < 0.05). Salivary ADAwas higher in patients with SS and non-SS sicca compared to controls (P<0.05 in both cases). Conclusion The results of the present study indicate that adiponectin and ADA are increased in the saliva of patients with SS. Clinical relevance Salivary adiponectin corrected by total protein can be a potential biomarker of SS.
Citation
Clinical Oral Investigations (2019) 23:1407–1414
item.page.embargo
1-ene-2999
Collections